Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
A rare 74% price-target hike from UBS is the headline for BEN, but the options market is pushing back. The put/call ratio has climbed to a two-standard-deviation extreme even as the stock slides further from the level where the analyst made his call.
Michael Brown at UBS assumed coverage on 7 October with a Buy rating and a target of $40, up from a prior analyst's $23. At Tuesday's close of $31.18, that implies roughly 28% upside. The 74% lift in the price target is one of the more aggressive opening moves seen on a large-cap asset manager in recent months.
Not everyone agrees. Barclays' Benjamin Budish cut his target to $34 from $36 on Tuesday, maintaining Equal-Weight. TD Cowen trimmed to $38 from $40, holding Buy. JP Morgan nudged its Neutral target up a dollar to $35. The consensus mean sits at $35.46, well below UBS's marker.
Evercore ISI maintains an Underperform with a $35 target, a reminder that one firm's aggressive entry point is another's exit.
The put/call ratio hit 0.6308 on Monday, 2.0 standard deviations above its 20-day mean of 0.554. That is the highest PCR reading since the 52-week peak of 1.04. Put demand picking up on a down day, BEN fell 1.98% Tuesday, suggests a portion of the market is buying downside protection rather than chasing the UBS thesis.
The stock is now down 7.3% over the past month and off 3.9% on the week. Earnings are due 6 November, and recent history shows BEN can move sharply: the July print produced a 6.2% one-day gain.
Short interest at 3.27% of free float is modest. It fell 12.3% in the week ended 9 October to the lowest level since late September, before ticking back slightly. Availability in the lending market stands at 1,534%, meaning there are more than fifteen shares available to borrow for every one already borrowed. Shorts face no supply constraint, but the position is not large enough to be a primary driver either way.
Two factor scores are worth noting. EPS momentum over 30 days ranks at the 96th percentile. The 90-day reading sits at the 91st percentile. The analyst recommendation differential ranks at the 98th percentile, reflecting how spread out the views are across the street. The ORTEX short score of 43.4 has edged down from 49.0 at end-September, consistent with the modest short-interest retreat.
Retail attention is also elevated: Wikipedia page-view data shows a z-score of 2.15 against the stock's own 90-day history as of 28 September, pointing to above-average public interest in the name heading into earnings.
What to watch: whether the options skew normalises as the November earnings date approaches, or extends toward the 52-week PCR high of 1.04.
See the live data behind this article on ORTEX.
Open BEN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
